Zheng Quan Shi Bao Wang·2025-08-07 10:05Core Viewpoint - Fosun Pharma's subsidiary, Hanhui, has received FDA approval to conduct a Phase I clinical trial for HLX43, a PD-L1 targeted antibody-drug conjugate for the treatment of thymic carcinoma [1] Company Summary - Fosun Pharma announced on August 7 that its subsidiary, Hanhui, has been granted approval by the U.S. FDA to initiate a Phase I clinical trial for HLX43 [1] - The clinical trial will focus on thymic carcinoma and is planned to be conducted in multiple global centers, including Australia, Japan, and the United States, once conditions are met [1] Industry Summary - The approval of HLX43 for thymic carcinoma represents a significant advancement in the oncology sector, particularly in targeted therapies [1] - The global multi-center clinical research indicates a strategic approach to expanding the drug's market potential across different regions [1]